{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:28:28Z","timestamp":1788272908582,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>\n                    The identification of\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    mutations in breast cancer patients is crucial. Successful identification of the mutations has the potential to alter disease treatment and healthcare management of patients whose relatives harbor pathogenic\/likely pathogenic (P\/LP) variants. In this retrospective analysis, patient- and disease-specific medical data were analyzed in a cohort of breast cancer patients with a known\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    status who were treated between 2019\u20132021. The prevalence and type of\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    P\/LP variants, and their relation to the histopathological data of the cancers, were studied. The presence of one or more clinical criteria leading to germline testing, the outcome of patient management, and family member outcomes were collected. Germline variants were found in 67\/259 cases and included 61 P\/LP alterations and six \u201cvariants of unknown significance\u201d (VUS) of the\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    genes. A spectrum of 31 different variants was detected; eight of them occurred in more than one patient, of which three (detected in 26 cases) belonged to the mutations most prevalently detected by the previously used technology in Hungary. The likelihood of revealing a pathogenic\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    mutation increased with the number of risk criteria for germline testing. The presence of three or more risk criteria was predictive for carrying a\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    mutation with an odds ratio (OR) of 10.65 (95% CI 5.20\u201321.80, p &amp;lt; 0.001). Among the histopathology data, a higher rate of grade 3 or triple negative breast cancer was found among\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    P\/LP variant carriers as compared to that in non-carriers. For ultimately revealing a\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    P\/LP variant, a positive family history (OR 6.69, 95% CI 1.82\u201324.64, p = 0.003) and triple negative breast cancer (OR 5.65, 95% CI 2.73\u201311.71, p &amp;lt; 0.001) were the strongest independent predictive factors. Knowing of\n                    <jats:italic>gBRCA1\/2<\/jats:italic>\n                    alterations meant healthcare management was modified in 86.9% of cases. Germline testing for breast cancer patients, guided by current protocols, is essential for optimizing patient care. Adhering to established clinical criteria facilitates effective patient selection while preventing the unnecessary expansion of testing to average-risk populations. Keywords:\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    , breast cancer, cancer susceptibility genes, germline testing, medical genetics.\n                  <\/jats:p>","DOI":"10.3389\/pore.2026.1612238","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:10:21Z","timestamp":1771567821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Germline BRCA testing in routine clinical practice: a single-center experience"],"prefix":"10.3389","volume":"32","author":[{"given":"Aliz","family":"Nikol\u00e9nyi","sequence":"first","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Dobi","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"S\u00e1ntha","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"K\u00f3sz\u00f3","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"Iv\u00e1nyi","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton Zsolt","family":"Enyedi","sequence":"additional","affiliation":[{"name":"Delta Bio 2000 Ltd.","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Priskin","sequence":"additional","affiliation":[{"name":"Delta Bio 2000 Ltd.","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Cs\u00e1nyi","sequence":"additional","affiliation":[{"name":"Delta Bio 2000 Ltd.","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Pat\u00f3cs","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriett","family":"Butz","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and The National Tumour Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Centre","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roz\u00e1lia","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kah\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12032-022-01804-x","article-title":"Risk factors for breast cancer in women: an update review","volume":"39","author":"Fakhri","year":"2022","journal-title":"Med Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ejhg.2008.212","article-title":"Breast cancer susceptibility: current knowledge and implications for genetic counselling","volume":"17","author":"Ripperger","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","article-title":"Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","volume":"7","author":"Fackenthal","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","article-title":"Hereditary breast cancer; Genetic penetrance and current status with BRCA","volume":"234","author":"Mahdavi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.6004\/jnccn.2023.0046","article-title":"NCCN guidelines\u00ae insights: breast cancer screening and diagnosis, version 1.2023","volume":"21","author":"Bevers","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctro.2018.01.001","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"B10","article-title":"Pre-specified analyses of IDFS, DDFS and OS 10 years from first patient","volume-title":"(FPI) in the OlympiA trial of adjuvant olaparib in germline BRCA1\/2 mutation-associated breast cancer, SABCS2024 presentation","author":"Garber","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clbc.2024.02.020","article-title":"PARP inhibitor for neoadjuvant therapy in HER2-Negative breast cancer: a systematic review and meta-analysis of efficacy and safety","volume":"24","author":"Jia","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: randomized phase II study of neoadjuvant cisplatin Versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-Negative breast cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13053-019-0111-y","article-title":"The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis","volume":"17","author":"Caramelo","year":"2019","journal-title":"Hered Cancer Clin Pract"},{"key":"B14","unstructured":"Klinikai genetika tagozat Az emberi er\u0151forr\u00e1sok miniszt\u00e9riuma eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelve A genetikai tan\u00e1csad\u00e1sr\u00f3l\n          \n          \n          2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American college of medical genetics and genomics (ACMG)","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","article-title":"ESMO recommendations on clinical reporting of genomic test results for solid cancers","volume":"35","author":"van de Haar","year":"2024","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"61845","DOI":"10.18632\/oncotarget.11259","article-title":"Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples","volume":"7","author":"Enyedi","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.4143\/crt.2021.1078","article-title":"Reclassification of five BRCA1\/2 variants with unknown significance using complex functional study","volume":"54","author":"Bozsik","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","article-title":"Founder BRCA1\/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control","volume":"1","author":"Janavi\u010dius","year":"2010","journal-title":"EPMA J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","first-page":"i6357","DOI":"10.1136\/bmj.i6357","article-title":"Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after angelina Jolie's New York times editorial","volume":"355","author":"Desai","year":"2016","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-society of surgical oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2232787","DOI":"10.1001\/jamanetworkopen.2022.32787","article-title":"Clinical utility of universal germline genetic testing for patients with breast cancer","volume":"5","author":"Whitworth","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.19.02190","article-title":"Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer","volume":"38","author":"Yadav","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","volume":"110","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1210\/clinem\/dgae300","article-title":"Cost-effectiveness of genetic testing of endocrine tumor patients using a comprehensive hereditary cancer gene panel","volume":"109","author":"Pat\u00f3cs","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e196400","DOI":"10.1001\/jamaoncol.2019.6400","article-title":"Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer","volume":"6","author":"Kurian","year":"2020","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2356078","DOI":"10.1001\/jamanetworkopen.2023.56078","article-title":"Cost-effectiveness of population-based multigene testing for breast and ovarian cancer prevention","volume":"7","author":"Guo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.3390\/ijerph19074314","article-title":"Spectrum of BRCA1\/2 mutations in Romanian breast and ovarian cancer patients","volume":"19","author":"Vidra","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4274\/ejbh.galenos.2020.6346","article-title":"Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study","volume":"17","author":"Atc\u0131","year":"2021","journal-title":"Eur J Breast Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12546","DOI":"10.3390\/ijms252312546","article-title":"Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background","volume":"25","author":"Nagy","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/cancers14082006","article-title":"Male breast cancer: from molecular genetics to clinical management","volume":"14","author":"Pensabene","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13058-016-0671-y","article-title":"Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the consortium of investigators of modifiers of BRCA1\/2","volume":"18","author":"Silvestri","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0134408","DOI":"10.1371\/journal.pone.0134408","article-title":"Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population","volume":"10","author":"Wong","year":"2015","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4132\/jptm.2020.04.07","article-title":"Clinicopathological characteristics of BRCA-Associated breast cancer in Asian patients","volume":"54","author":"Kim","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.24200","article-title":"BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer [published correction appears in cancer. 2009 Jun 15;115(12):2804]","volume":"115","author":"Hall","year":"2009","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1054\/bjoc.2001.2103","article-title":"Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients","volume":"85","author":"de Bock","year":"2001","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41416-021-01597-2","article-title":"Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer","volume":"126","author":"Guzm\u00e1n-Arocho","year":"2022","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/s0140-6736(97)07065-7","article-title":"Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1","volume":"351","author":"Verhoog","year":"1998","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N","article-title":"The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study","volume":"83","author":"Armes","year":"1998","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.breast.2006.12.003","article-title":"BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study","volume":"16","author":"Musolino","year":"2007","journal-title":"Breast"},{"key":"B49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijc.30692","article-title":"The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing","volume":"141","author":"Lang","year":"2017","journal-title":"Int J Cancer"},{"key":"B50","first-page":"2465","article-title":"Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer","volume":"3","author":"Foulkes","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","article-title":"BRCA-associated breast cancer in young women","volume":"16","author":"Robson","year":"1998","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w","article-title":"Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage","volume":"77","author":"Marcus","year":"1996","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.21.00640","article-title":"Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast","volume":"39","author":"Yadav","year":"2021","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-Positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9734","DOI":"10.3390\/curroncol30110706","article-title":"Estrogen-receptor-low-positive breast cancer: pathological and clinical perspectives","volume":"30","author":"Malainou","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:10:23Z","timestamp":1771567823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":58,"alternative-id":["10.3389\/pore.2026.1612238"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612238","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1612238"}}